Blood Analyzer Simultaneously Provides CBC and CRP
|
By LabMedica International staff writers Posted on 23 Jul 2012 |

Image: The Microsemi Hematology Analyzer (Photo courtesy of Horiba Medical).
A compact analyzer simultaneously provides a complete blood count (CBC) and C-reactive protein (CRP) from just 18 μL of blood in only 4 minutes. After a highly successful release in Japan, the instrument is now available in Europe.
Horiba Medical (Kyoto, Japan), specialists in automated in vitro diagnostic systems for hematology and chemistry analysis, launched the Microsemi CRP hematology analyzer.
The Microsemi CRP provides information of great clinical value enabling quicker and more accurate medical decisions to ultimately reduce hospitalization times and patient costs. Its powerful CRP analysis allows the screening of patient samples to detect the presence of inflammation caused by bacterial infections, or other treatable inflammatory disease.
Measurement is possible immediately after blood sample collection, making this analyzer the ideal choice for emergency testing. The Microsemi CRP can also be used to assess infection and inflammatory conditions that require progressive observation. In addition, its microsampling capabilities are ideal for pediatric blood analysis, requiring only 10µL for CBC and 18 µL for CBC+CRP, and can be used with capillary, as well as venous blood samples.
Comprehensive and efficient on-board software, color touch screen, alongside fast and easy access to results, adds to the Microsemi CRP’s success. Design features have created an environmentally friendly model (using a noncyanide reagent for hemoglobin measurement) that is compact, lightweight, and quiet. The Microsemi CRP does not require specialized staff.
According to Cleve Wright, UK general manager, Horiba Medical, “With over 2000 instruments successfully being used in Japan to date, UK clinicians can now benefit from the Microsemi CRP’s accuracy, convenience, and ability to support early and rapid diagnosis of patients.”
Related Links:
Horiba Medical
Horiba Medical (Kyoto, Japan), specialists in automated in vitro diagnostic systems for hematology and chemistry analysis, launched the Microsemi CRP hematology analyzer.
The Microsemi CRP provides information of great clinical value enabling quicker and more accurate medical decisions to ultimately reduce hospitalization times and patient costs. Its powerful CRP analysis allows the screening of patient samples to detect the presence of inflammation caused by bacterial infections, or other treatable inflammatory disease.
Measurement is possible immediately after blood sample collection, making this analyzer the ideal choice for emergency testing. The Microsemi CRP can also be used to assess infection and inflammatory conditions that require progressive observation. In addition, its microsampling capabilities are ideal for pediatric blood analysis, requiring only 10µL for CBC and 18 µL for CBC+CRP, and can be used with capillary, as well as venous blood samples.
Comprehensive and efficient on-board software, color touch screen, alongside fast and easy access to results, adds to the Microsemi CRP’s success. Design features have created an environmentally friendly model (using a noncyanide reagent for hemoglobin measurement) that is compact, lightweight, and quiet. The Microsemi CRP does not require specialized staff.
According to Cleve Wright, UK general manager, Horiba Medical, “With over 2000 instruments successfully being used in Japan to date, UK clinicians can now benefit from the Microsemi CRP’s accuracy, convenience, and ability to support early and rapid diagnosis of patients.”
Related Links:
Horiba Medical
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
Head and neck squamous cell carcinoma affects hundreds of thousands of people worldwide each year, yet response rates to immunotherapy remain low. Clinicians lack reliable, minimally invasive tools to... Read more
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








